Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
作者： S. Wu , R.K. Singh
DOI: 10.2174/156652411800615153
关键词:
摘要: Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure agents attributed to development therapy resistance. Accumulated evidence points apoptotic defect cells and surge signals stimulated by cytotoxic drugs, as a way that tumors circumvent chemotherapy. An overview inhibitors developed against these growth/survival factors, which are potential partners be combined systemic chemotherapy, will discussed. The escape mechanism from molecular also suggests "vertical" or "horizontal" combination molecularly targeted therapies. A better understanding interactions between simultaneously used rationale for provide new insights improve quality life in patients advanced melanoma.
eurekaselect.com
elsevier.com参考文章(72)
M. Pisano, P. Baldinu, M.C. Sini, P.A. Ascierto, F. Tanda, G. Palmieri, Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications Annals of Oncology. ,vol. 19, pp. 2092- 2093 ,(2008) , 10.1093/ANNONC/MDN672
Katayoun I. Amiri, Linda W. Horton, Bonnie J. LaFleur, Jeffrey A. Sosman, Ann Richmond, Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Research. ,vol. 64, pp. 4912- 4918 ,(2004) , 10.1158/0008-5472.CAN-04-0673
Natasha Y. Frank, Armen Margaryan, Ying Huang, Tobias Schatton, Ana Maria Waaga-Gasser, Martin Gasser, Mohamed H. Sayegh, Wolfgang Sadee, Markus H. Frank, ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma Cancer Research. ,vol. 65, pp. 4320- 4333 ,(2005) , 10.1158/0008-5472.CAN-04-3327
Bret B. Friday, Chunrong Yu, Grace K. Dy, Paul D. Smith, Liang Wang, Stephen N. Thibodeau, Alex A. Adjei, BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins Cancer Research. ,vol. 68, pp. 6145- 6153 ,(2008) , 10.1158/0008-5472.CAN-08-1430
Eleni Linos, Susan M. Swetter, Myles G. Cockburn, Graham A. Colditz, Christina A. Clarke, Increasing Burden of Melanoma in the United States Journal of Investigative Dermatology. ,vol. 129, pp. 1666- 1674 ,(2009) , 10.1038/JID.2008.423
Karen Cichowski, Pasi A. Jänne, Drug discovery: inhibitors that activate. Nature. ,vol. 464, pp. 358- 359 ,(2010) , 10.1038/464358A
Keiran S.M. Smalley, Nikolas K. Haass, Patricia A. Brafford, Mercedes Lioni, Keith T. Flaherty, Meenhard Herlyn, Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Molecular Cancer Therapeutics. ,vol. 5, pp. 1136- 1144 ,(2006) , 10.1158/1535-7163.MCT-06-0084
Matthias Preusser, Robert Charles Janzer, Jörg Felsberg, Guido Reifenberger, Marie-France Hamou, Annie-Claire Diserens, Roger Stupp, Thierry Gorlia, Christine Marosi, Harald Heinzl, Johannes A Hainfellner, Monika Hegi, Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathology. ,vol. 18, pp. 520- 532 ,(2008) , 10.1111/J.1750-3639.2008.00153.X
F. Stephen Hodi, Gerald P. Linette, Jon Richards, James W. Jakub, Muralidhar Beeram, Stefano Tarantolo, Sanjiv Agarwala, Gary Frenette, Igor Puzanov, Lee Cranmer, Karl Lewis, John Kirkwood, J. Michael White, Chenghua Xia, Kiran Patel, Evan Hersh, David F. McDermott, Jeffrey A. Sosman, Rene Gonzalez, Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group Journal of Clinical Oncology. ,vol. 26, pp. 2178- 2185 ,(2008) , 10.1200/JCO.2007.14.8288
Michele Del Vecchio, Roberta Mortarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, Mario R. Sertoli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone, Emilio Bajetta, Andrea Anichini, BEVACIZUMAB PLUS FOTEMUSTINE AS FIRST-LINE TREATMENT IN METASTATIC MELANOMA PATIENTS: CLINICAL ACTIVITY AND MODULATION OF ANGIOGENESIS AND LYMPHANGIOGENESIS FACTORS Clinical Cancer Research. ,vol. 16, pp. 5862- 5872 ,(2010) , 10.1158/1078-0432.CCR-10-2363